Briefing
3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
With median follow-up 43.4 months, adjuvant nivolumab improved DFS versus placebo in the ITT population (median 21.9 vs 11.0 months; HR 0.74, 95% CI 0.61-0.90). In the exploratory Signatera analysis, DFS HR was 0.35 (95% CI 0.2-0.7) in patients who were ctDNA-positive at cycle 1 day 1 (median 7.4 vs 2.8 months) and 0.99 (95% CI 0.5-1.9) in those who were ctDNA-negative.
- Design: oral
- n: 709 randomized (353 nivolumab, 356 placebo); ctDNA evaluable at cycle 1 day 1 in 133 (18.8%), of whom 54 (40.6%) were ctDNA-positive
- Assay: Natera Signatera (exploratory)